TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03813641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Experimental: Oxaliplatin + Raltitrexed + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
Study: NCT01891682

Intervention type: OTHER
Intervention: Observational
Description: Observational, Translational non-treatment study
Study: NCT01281956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-00023
Description: PRX-00023 (Selective 5HT1A agonist)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-00023
Description: PRX-00023 (Selective 5HT1A agonist)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02150681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Description: This is an 8-week treatment for women with mood disorders. The focus of sessions 1 through 4 is to establish a foundation of mindfulness practice and bringing nonjudgmental awareness to the present moment, beginning with concrete targets of attention and moves to more emotionally challenging and abstract targets (e.g., depression-specific thoughts). Participants are guided to become aware of the automatic patterns of their minds and in such moments to return attention to thoughts, feelings and body sensations. Participants engage experientially with the ways in which thoughts and emotions become engaged with rumination. In sessions 5 through 8, participants learn to extend their basic mindfulness skills to become aware of relapse risk signs and develop prevention plans.
Study: NCT02328794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette free access
Description: Participants in this arn will be given free access to e-cigarettes to help quit smoking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette/NRT/Zyban/Chantix Choice
Description: Participants in this arn will be given free access to cessation aids to help quit smoking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outcome Incentive arm
Description: Participants in this arm will be earn incentives across 6 months for verified abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss framing incentive arm
Description: Participants in this arm will be told they have a pre-funded account with money that is theirs if they quit smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will have access to information and advice on quitting smoking. This is a control and no actual intervention will be applied.
Study: NCT02530918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7080a
Description: 1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7080a
Description: 1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7080a
Description: 1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7080a
Description: 1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution
Study: NCT04399538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Tablet
Study: NCT02126436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
Study: NCT04399538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT02726984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-sodium fluoride PET/MR
Description: 18F-sodium fluoride PET/MR combining 3Tesla (3T) MR and PET producing 127 slices of 2 mm on an axial field of view of 26 cm. 18F-sodium fluoride (2 à 4 megabecquerel/kilogram (MBq/kg)) will be injected 60 min before.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-sodium fluoride PET/MR
Description: 18F-sodium fluoride PET/MR combining 3Tesla (3T) MR and PET producing 127 slices of 2 mm on an axial field of view of 26 cm. 18F-sodium fluoride (2 à 4 megabecquerel/kilogram (MBq/kg)) will be injected 60 min before.
Study: NCT02657070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement-Induced Movement Therapy (RIMT)
Description: 6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS) with augmented visuomotor feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR-based motor rehabilitation in RGS without augmented feedback
Description: 6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS)
Study: NCT02372058

Intervention type: DEVICE
Group type: OTHER
Intervention: BiliCare
Description: Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device
Study: NCT02339701

Intervention type: RADIATION
Group type: OTHER
Intervention: IMRT

Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT
Study: NCT03108963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine and Metformin
Description: L-carnitine plus Metformin was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
Study: NCT00515398

Intervention type: OTHER
Intervention: Observation
Description: Ex vivo administration of AT2220
Study: NCT01839968

Intervention type: OTHER
Intervention: Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma
Study: NCT02359591

Intervention type: OTHER
Intervention: text-based or multimedia
Description: subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
Study: NCT04131959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb 300 mL device
Description: Intra-operative CytoSorb hemoadsorption of ticagrelor during cardiopulmonary bypass
Study: NCT03050398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: ribociclib + letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: ribociclib + letrozole
Study: NCT00624039

Intervention type: OTHER
Group type: OTHER
Intervention: UBM with pilocarpine in presbyopia
Description: ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
Study: NCT02411344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: * Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles~* Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle~* Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery).
Study: NCT01627795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D and Oshadi R
Description: anti cancer agents
Study: NCT00908596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid disodium (Primovist, BAY86-4873)
Description: Primovist/Eovist in approved indications at approved dosages
Study: NCT04839432

Intervention type: BEHAVIORAL
Intervention: implementation of albumin solution in the priming of the cardiopulmonary bypass machine
Description: In March 2019, the investigators initiated a new priming fluid policy strategy aiming at replacing our traditional pure crystalloid fluid administration for an albumin one in order to decrease the relatively high-rate of observed pulmonary complications
Study: NCT01500655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional nerve block
Description: a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional nerve block
Description: a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.
Study: NCT04022577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Therapy
Description: Motivational interviewing-based AT in this study was based on Chien et al., (2016) and Gray et al., (2010) eight-session AT using the motivational interviewing technique (and principles of cognitive behavioral therapy).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: The control group received routine care
Study: NCT00510146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
Study: NCT01500655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter
Description: After an ultrasound guided nerve block is performed a catheter is placed under the fascia iliaca and an infusion of ropivacaine 0.2% running at 0.15 ml/kg/hour is administered for 48 hours.
Study: NCT04465084

Intervention type: OTHER
Group type: OTHER
Intervention: Case
Description: Battery of standardised and normalised tests evaluating different cognitive functions Experimental language tasks MRI
Study: NCT04465084

Intervention type: OTHER
Group type: OTHER
Intervention: Withness
Description: Experimental language tasks MRI
Study: NCT03048071

Intervention type: OTHER
Intervention: Data collection within medical files
Description: Data collection within medical files

Intervention type: OTHER
Intervention: Data collection within medical files
Description: Data collection within medical files
Study: NCT00386230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZDV Short (mother)-Short (infant): Comparison of zidovudine durations
Description: Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZDV Short (mother)-Long (infant): Comparison of zidovudine durations
Description: Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZDV Long (mother)-Short (infant): Comparison of zidovudine durations
Description: Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZDV Long (mother)-Long (infant): Comparison of zidovudine durations
Description: Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)
Study: NCT03627650

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lipofilling/ fat grafting
Description: liposuction, processing/ cleaning of fat tissue; reinjection with sharp needle transcutaneous

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placebo injection
Study: NCT00565097

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Study: NCT03447964

Intervention type: OTHER
Intervention: dosing of sphingolipids
Description: - Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine

Intervention type: OTHER
Intervention: dosing of sphingolipids
Description: - Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
Study: NCT04540731

Intervention type: OTHER
Intervention: This is an observational study without intervention
Description: This is an observational study without intervention
Study: NCT00510146

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets, oral, once daily at bedtime, 6 weeks
Study: NCT04181489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg d0
Study: NCT02242370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of telmisartan
Study: NCT02855177

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as suspension administered every 8 hours, with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: 500 mg suspension administered every 8 hours, with food
Study: NCT02493530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.~Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.~Expansion will commence after proper combination doses of both agents is established.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Study: NCT02485756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational handout
Description: Topics include: interactions between AED and certain hormonal contraceptives, Center for Disease Control and Prevention (CDC) recommendations for alternative contraceptive methods that are not known to interact with AEDs, contraceptive failure rates
Study: NCT04183569

Intervention type: OTHER
Intervention: Sequencing RNA.
Description: RNA-seq, central pivot between genomics and proteomics allows to make the connection between the observed mutations and alteration of protein expression with the identification and quantification of RNA. Thus, we can attest to the expression of mutations identified on DNA, protein and understand whether deregulation is linked to dysregulation of transcription or post-translational modification
Study: NCT01441245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide infusion
Description: Patients were randomized in a 1:1 ratio to receive furosemide dose divided into twice-daily bolus injection (group 0) or continuous infusion (group 1)(mixed as a 1:1 ratio in 5% dextrose in water) for a time period ranging from 72 to 120 hours. The mean daily diuretic dosage was similar in the two groups. The median time from presentation to randomization was 16 hours, and the median duration of study-drug administration was 112± 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide infusion
Description: Patients were randomized in a 1:1 ratio to receive furosemide dose divided into twice-daily bolus injection (group 0) or continuous infusion (group 1)(mixed as a 1:1 ratio in 5% dextrose in water) for a time period ranging from 72 to 120 hours. The mean daily diuretic dosage was similar in the two groups. The median time from presentation to randomization was 16 hours, and the median duration of study-drug administration was 112± 24 hours
Study: NCT01210014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zinc sulphate 220mg/day in one dosage
Description: patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo: one dosage
Description: patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again.
Study: NCT02488967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04181489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 d0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m2 d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4mg/m2 (maximum 2mg) d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 60mg/m2 d1-5
Study: NCT02418962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Sodium chloride solution for injection
Study: NCT02488967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT03337048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath
Description: SpeediCath is a standard intermittent catheter that is on the market.